The historical rank and industry rank for Taysha Gene Therapies's FCF Margin % or its related term are showing as below:
TSHA'
s FCF Margin % Range Over the Past 10 Years
Min: -4526.74 Med: -969.65 Max: -520.27
Current: -1543.73
During the past 7 years, the highest FCF Margin % of Taysha Gene Therapies was -520.27%. The lowest was -4526.74%. And the median was -969.65%.
TSHA's FCF Margin % is ranked worse than 82.92% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs TSHA: -1543.73
Taysha Gene Therapies FCF Margin % Related Terms
Taysha Gene Therapies FCF Margin % Historical Data
* Premium members only.
The historical data trend for Taysha Gene Therapies's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Taysha Gene Therapies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (TSHA) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Taysha Gene Therapies and its competitors. According to the industry distribution chart, Taysha Gene Therapies ranks #796 out of 960 companies in the Biotechnology industry, placing it in the top 82.9%.
Is Taysha Gene Therapies' FCF Margin % too high?
Taysha Gene Therapies' current FCF Margin % is 0.00%. Based on the distribution chart, Taysha Gene Therapies ranks #796 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' FCF Margin % compare to GENB and ATAI?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #796 out of 960 companies for FCF Margin %. This places Taysha Gene Therapies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Taysha Gene Therapies and its competitors. Taysha Gene Therapies's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.70, compared to a current price of $6.45 — trading 820.7% above its estimated fair value. The current FCF Margin % is 0.00%. Taysha Gene Therapies' overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $6.45 is trading 820.7% above its estimated GF Value™ of $0.70.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
FCF Margin %: 0.00%
GF Value™: $0.70 vs. price of $6.45 (820.7% above fair value)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
27GF Score
Get the complete analysis for TSHA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
